OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis

BACKGROUND: Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in children....

Descripción completa

Detalles Bibliográficos
Autores principales: Buendía, Jefferson Antonio, Patiño, Diana Guerrero, Lindarte, Erika Fernanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724379/
https://www.ncbi.nlm.nih.gov/pubmed/36474205
http://dx.doi.org/10.1186/s12890-022-02264-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724379/
https://www.ncbi.nlm.nih.gov/pubmed/36474205
http://dx.doi.org/10.1186/s12890-022-02264-9

Ejemplares similares